Gh Research Plc (GHRS) Stock Price, Quote & News

Company Profile

GH Research PLC, together with its subsidiary, a clinical-stage biopharmaceutical company, engages in developing treatments for depression in the United States. Its lead product candidate is GH001, an inhalable mebufotenin product candidate, which is in phase 2b clinical trial for treating patients with treatment-resistant depression; and in phase 2a clinical trial for treating bipolar II disorder and a current major depressive episode, as well as female patients with postpartum depression. The...

Industry: Biotechnology

Sector: Healthcare

Phone: 353 1 437 8334

Website: www.ghres.com

Address:

Joshua Dawson House, Dawson Street, Dublin, Ireland

NorthStarStats Mar. 11 at 8:57 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $BBIO Score: 100|Catalyst Year, $HIMX Score: 95, $PYXS Score: 95, $GHRS Score: 88 |Showing up regularly- Watch, $RIVN Score: 73|R2 Reveal and Launch March 12

0 · Reply

NorthStarStats Mar. 10 at 2:30 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $PYXS Score: 95.00 | >350% implied upside|Earnings, $AVGO Score 95.00 |100B+ in AI chip revenue expected, $GHRS Score: 95.00 |Solid Cash Runway| $42 upgrade, $DNLI Score: 95.00 |PDUFA tividenofusp alfa April 5, $LYV Score 73.00 |DOJ Setlmnt|Venue Nation Expansion

0 · Reply

NorthStarStats Mar. 8 at 4:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores

0 · Reply

Doozio Mar. 7 at 6:22 PM

$GHRS 🐒🍌🧠⏰♾️

0 · Reply

NJgolfer Mar. 7 at 6:10 PM

$GHRS weekly buy signal last week when market was down shows impressive relative strength. Stop below $14.50

0 · Reply

ChristopherMcC Mar. 5 at 4:37 PM

$HELP ...$ATAI $CMPS $GHRS $DFTX ... blame Helus, I know I do.

1 · Reply

TheRealShortSqueezy Mar. 3 at 4:30 PM

$ATAI: Recent Clinical Milestones and Upcoming Investor Engagements 🧠 ATAIBeckley continues to advance its pipeline with two important recent developments: 🥇 EMP-01 : Positive topline results in social anxiety disorder 🥈 BPL-003 : Successful End of Phase 2 FDA meeting in treatment-resistant depression, supporting the path toward Phase 3 These milestones mark continued progress across ATAIBeckley’s clinical portfolio and reinforce execution against key development objectives. Upcoming Events: 📅 March 4 : TD Cowen 46th Annual Health Care Conference 📅 March 6 : ATAIBeckley Virtual Investor Day 📅 March 10 : Jefferies Biotech on the Beach 📅 March 11 : Leerink Global Healthcare Conference An active period ahead as ATAIBeckley shares further insights into its programs and strategy. Communicated disclaimer: https://bit.ly/4ci8Ftu Sector Peers: $CMPS $DFTX $GHRS $HELP

1 · Reply

NorthStarStats Mar. 3 at 6:40 AM

For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. $GHRS Score: 98.00, $CVS Score: 98.00, $DV Score: 95.00, $RCUS Score: 95.00, $XYZ Score 95.00

0 · Reply

TheRealShortSqueezy Feb. 26 at 12:32 PM

$ATAI Releases Major Clinical Pipeline News 📰 ATAI Life Sciences announced positive topline results from its exploratory Phase 2a clinical trial evaluating EMP-01 for the treatment of social anxiety disorder. Trial Overview and Key Findings 👉🏽Randomized, double-blind, placebo-controlled exploratory trial 👉🏽EMP-01 demonstrated encouraging efficacy signals in patients with social anxiety disorder 👉🏽Treatment was reported to be generally well tolerated Strategic Importance 👉🏽Supports continued advancement of EMP-01 into future clinical trials 👉🏽Strengthens ATAI’s position in psychedelic-inspired therapeutics 👉🏽Reinforces the company’s focus on innovative psychiatric treatments EMP-01 remains in early-stage development, but the positive Phase 2a data marks an important step forward in ATAI’s efforts to expand treatment options for social anxiety disorder. Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $GHRS $HELP $RLMD $SILO

0 · Reply

OfficialStocktwitsUser Feb. 25 at 2:54 PM

$GHRS RSI: 49.78, MACD: 0.0491 Vol: 0.58, MA20: 15.47, MA50: 14.93 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3

Mar 5, 2026, 7:00 AM EST - 10 days ago

GH Research Reports Full Year 2025 Financial Results and Provides Business Update

Jan 5, 2026, 9:37 AM EST - 2 months ago

FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years

Jan 5, 2026, 7:00 AM EST - 2 months ago

GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026

Jan 4, 2026, 8:30 AM EST - 2 months ago

GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision

Jan 2, 2026, 4:01 PM EST - 2 months ago

GH Research to Announce IND Status for GH001

Nov 6, 2025, 7:00 AM EST - 4 months ago

GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates

Oct 13, 2025, 2:07 PM EDT - 5 months ago

Depression-Focused GH Research Shares Could See Significant Upside: Analyst

Oct 9, 2025, 7:00 AM EDT - 5 months ago

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

Aug 7, 2025, 7:00 AM EDT - 7 months ago

GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 23, 2025, 8:00 AM EDT - 8 months ago

GH Research Announces Global Pivotal Program Plans and Further Development Updates

Jun 20, 2025, 1:00 PM EDT - 9 months ago

GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule

May 15, 2025, 7:00 AM EDT - 10 months ago

GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting

May 8, 2025, 7:00 AM EDT - 11 months ago

GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates

Feb 27, 2025, 7:00 AM EST - 1 year ago

GH Research Reports Full Year 2024 Financial Results and Provides Business Updates

Feb 4, 2025, 8:52 PM EST - 1 year ago

GH Research Announces Pricing of $150 Million Public Offering

Feb 3, 2025, 4:03 PM EST - 1 year ago

GH Research Announces Proposed Public Offering

Feb 3, 2025, 10:55 AM EST - 1 year ago

Why Is GH Research Stock Trading Higher On Monday?

Feb 3, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction

Jan 31, 2025, 4:01 PM EST - 1 year ago

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

Jan 10, 2025, 7:00 AM EST - 1 year ago

GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents

Nov 14, 2024, 7:00 AM EST - 1 year ago

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:05 AM EDT - 1 year ago

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

Sep 3, 2024, 7:00 AM EDT - 1 year ago

GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer

May 3, 2024, 7:00 AM EDT - 2 years ago

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

Feb 29, 2024, 7:00 AM EST - 2 years ago

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

Jan 18, 2024, 4:30 PM EST - 2 years ago

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

Nov 9, 2023, 4:45 PM EST - 2 years ago

GH Research Reports Third Quarter Financial Results and Provides Business Updates

Sep 29, 2023, 4:45 PM EDT - 2 years ago

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

Aug 23, 2023, 7:00 AM EDT - 2 years ago

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

Jun 16, 2023, 11:06 AM EDT - 2 years ago

GH Research: But Toad Venom Is A Controlled Substance

May 11, 2023, 7:30 AM EDT - 3 years ago

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

Mar 2, 2023, 7:00 AM EST - 3 years ago

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Jan 15, 2023, 11:45 AM EST - 3 years ago

Psychedelic Sunday: Competitive Strategies

ATAI CMPS HELP DFTX

Jan 9, 2023, 7:30 AM EST - 3 years ago

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Nov 10, 2022, 7:05 AM EST - 3 years ago

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

Aug 23, 2022, 7:00 AM EDT - 3 years ago

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

May 18, 2022, 7:00 AM EDT - 4 years ago

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

Mar 28, 2022, 7:04 AM EDT - 4 years ago

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Jan 19, 2022, 4:31 PM EST - 4 years ago

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

Dec 6, 2021, 2:16 PM EST - 4 years ago

GH Research Announces Positive Trial Results For Treatment-Resistant Depression

Dec 6, 2021, 10:15 AM EST - 4 years ago

GH Research Posts Data From Treatment-Resistant Depression Trial

Dec 6, 2021, 7:10 AM EST - 4 years ago

GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates

Sep 23, 2021, 5:25 PM EDT - 4 years ago

GH Research PLC Provides Business Updates and Reports Second Quarter 2021 Financial Results

Aug 15, 2021, 3:55 AM EDT - 4 years ago

GH Research: A Recent IPO Stock That Could Possibly Be A Trailblazer In A Hot Industry

Jun 25, 2021, 1:23 PM EDT - 5 years ago

7 Companies Go Public Today. What Investors Need to Know.

ELEV MCW TKNO ACXP

Jun 22, 2021, 8:25 PM EDT - 5 years ago

GH Research Seeks $125 Million IPO

NorthStarStats Mar. 11 at 8:57 AM

0 · Reply

NorthStarStats Mar. 10 at 2:30 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $PYXS Score: 95.00 | >350% implied upside|Earnings, $AVGO Score 95.00 |100B+ in AI chip revenue expected, $GHRS Score: 95.00 |Solid Cash Runway| $42 upgrade, $DNLI Score: 95.00 |PDUFA tividenofusp alfa April 5, $LYV Score 73.00 |DOJ Setlmnt|Venue Nation Expansion

0 · Reply

NorthStarStats Mar. 8 at 4:39 PM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $KR Score:90.00 (BREAKOUT WATCH), $SLDB Score: 95.00; MDA Conf.,Earnings,Phase 3 Trial, $GHRS Score: 95.00; Phase 3 Start Announcement, $FHTX Score: 85.00;Cash Runaway, $SBUX Score 70.00; Revenue +6% 600-650 new stores

0 · Reply

Doozio Mar. 7 at 6:22 PM

$GHRS 🐒🍌🧠⏰♾️

0 · Reply

NJgolfer Mar. 7 at 6:10 PM

$GHRS weekly buy signal last week when market was down shows impressive relative strength. Stop below $14.50

0 · Reply

ChristopherMcC Mar. 5 at 4:37 PM

$HELP ...$ATAI $CMPS $GHRS $DFTX ... blame Helus, I know I do.

1 · Reply

TheRealShortSqueezy Mar. 3 at 4:30 PM

1 · Reply

NorthStarStats Mar. 3 at 6:40 AM

0 · Reply

TheRealShortSqueezy Feb. 26 at 12:32 PM

0 · Reply

OfficialStocktwitsUser Feb. 25 at 2:54 PM

0 · Reply

BillionerOfKing Feb. 18 at 11:04 PM

$GHRS Current Stock Price: $16.10 Contracts to trade: $15.0 GHRS Feb 20 2026 Call Entry: $1.35 Exit: $2.08 ROI: 54% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

KristyZediker521 Feb. 18 at 12:47 PM

$GHRS Oncology biotech with platform science; execution cadence controls valuation.

0 · Reply

NorthStarStats Feb. 18 at 1:03 AM

For anyone following along, I developed a Python-based statistical scanner to identify stocks with near-term institutional accumulation and upward price momentum. Be careful out there folks. The market is vicious and scanner is consistently showing low scores for stocks. Here are the top 5: $NCLH Score 95, $CMPS Score 95, $GHRS Score 71, $CBOE Score 70, $ALL Score 70

0 · Reply

ChristopherMcC Feb. 5 at 4:56 PM

$HELP $DFTX $ATAI $CMPS $GHRS The only story that truly matters at this stage.

3 · Reply

BagHolderBuddy Feb. 4 at 3:12 PM

$GHRS is a clinical-stage biotech developing therapies for neurological disorders; its pipeline is early and represents a high-risk investment in a challenging therapeutic area.

0 · Reply

OfficialStocktwitsUser Feb. 2 at 12:14 PM

$GHRS RSI: 55.75, MACD: 0.5512 Vol: 1.07, MA20: 15.98, MA50: 14.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

twiggs462 Feb. 1 at 7:25 PM

$ATAI $GHRS received a "Final Rejection" from the US patent office on Jan 12th to broadly patent 5-MeO-DMT for depression. That reduces IP risk across the sector and puts the focus back on clinical results and delivery; areas where $ATAI is well positioned.

3 · Reply

Bbbb44444 Jan. 29 at 8:58 PM

$CMPS $ATAI $GHRS $DFTX Some interesting tidbits in this article. Frustration is growing (“It’s being called the medical revolution that wasn’t”). https://www.yahoo.com/news/articles/veterans-call-more-hhs-support-160923976.html

2 · Reply

Quantumup Jan. 23 at 7:50 PM

RBC Capital⬆️the PT on $GHRS to $40 from $33, reiterated at Outperform and said, Raising Price Target to $40 Following Psychedelics Symposium and Reiterating Outperform $JNJ $HELP ATAI CYBN MNMD CMPS RBC Capital additionally said: Following our Psychedelics Symposium and discussions with mgmt., payers, and docs, we are increasingly optimistic on GHRS's long-term sales opportunity with GH001 and are raising our price target to $40 from $33 based on updated assumptions about drug pricing in-line with Spravato. With EoP2 meeting later this year and pivotal trials initiation on track for later this year, we believe that GHRS remains a high quality mid-stage story in the emerging psychedelics space.

0 · Reply

Bbbb44444 Jan. 23 at 4:29 PM

$ATAI $CMPS $GHRS $DFTX The three most important questions to consider when evaluating these: 1. Efficacy If it doesn’t work better than SSRIs, it doesn’t matter how scalable it is. 2. Scalability (clinic throughput) If it requires 8–12+ hours of supervision, adoption caps out fast. 3. Durability Longer durability = fewer treatments = more payer-friendly. Commercial Viability (based on above and current data): 1. ATAI (BPL-003) 2. CMPS (COMP360) 3. GHRS (GH001) 4. DFTX (DT120) CMPS is already FDA-validated with a clear Phase 3 primary endpoint win in TRD, but it’s more operationally heavy. ATAI and GHRS are designing short-acting molecules, which would mean shorter experiences and faster discharge (more patients seen per day). DFTX may end up clinically excellent, but it’s a throughput killer.

2 · Reply

Roaring_Capybara Jan. 20 at 6:55 PM

$GHRS Exited Friday @$17.00. Buying some here at $15.77

0 · Reply

Roaring_Capybara Jan. 20 at 5:04 PM

$KYTX $GHRS KYTX looking strong. Back in at $8.50

0 · Reply

Market Cap	927.33M
Revenue (ttm)	0.00
Net Income (ttm)	-48.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	118,000
Avg Vol	409,584
Day's Range	N/A - N/A
Shares Out	62.03M
Stochastic %K	17%
Beta	1.00
Analysts	Strong Sell
Price Target	$39.25